SEC FORM
3
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
| 4505 EMPEROR BLVD. |
| SUITE 200 |
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
01/08/2020
|
3. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC
[ BCRX ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
|
10% Owner |
| X |
Officer (give title below) |
|
Other (specify below) |
| Exec Director, Finance - PAO |
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Common Stock |
848 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Emp. Stock Option (Right to Buy) |
03/21/2012 |
03/21/2021 |
Common Stock |
4,500 |
3.51 |
D |
|
| Emp. Stock Option (Right to Buy) |
03/01/2013 |
03/01/2022 |
Common Stock |
2,300 |
4.73 |
D |
|
| Emp. Stock Option (Right to Buy) |
01/01/2014 |
01/01/2023 |
Common Stock |
8,600 |
1.42 |
D |
|
| Emp. Stock Option (Right to Buy) |
05/26/2014 |
08/08/2023 |
Common Stock |
10,000 |
5.45 |
D |
|
| Emp. Stock Option (Right to Buy) |
01/20/2015 |
01/20/2024 |
Common Stock |
2,700 |
10.8 |
D |
|
| Emp. Stock Option (Right to Buy) |
01/01/2016 |
01/01/2025 |
Common Stock |
3,200 |
12.16 |
D |
|
| Emp. Stock Option (Right to Buy) |
12/29/2016
|
12/29/2025 |
Common Stock |
3,666 |
10.82 |
D |
|
| Emp. Stock Option (Right to Buy) |
05/23/2017
|
05/23/2026 |
Common Stock |
7,584 |
3.22 |
D |
|
| Emp. Stock Option (Right to Buy) |
08/31/2017 |
12/22/2024 |
Common Stock |
4,200 |
11.13 |
D |
|
| Emp. Stock Option (Right to Buy) |
02/27/2018
|
02/27/2027 |
Common Stock |
6,000 |
5.51 |
D |
|
| Emp. Stock Option (Right to Buy) |
12/20/2018
|
12/20/2027 |
Common Stock |
3,250 |
5.04 |
D |
|
| Emp. Stock Option (Right to Buy) |
12/20/2019
|
12/20/2028 |
Common Stock |
18,000 |
7.06 |
D |
|
| Emp. Stock Option (Right to Buy) |
12/17/2020
|
12/17/2029 |
Common Stock |
22,000 |
3.23 |
D |
|
| Explanation of Responses: |
|
| Remarks: |
|
|
Michael L. Jones |
01/17/2020 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
POWER OF ATTORNEY
January 15, 2020
The undersigned hereby constitutes and appoints Alane P.
Barnes, the Senior Vice President & Chief Legal Officer of BioCryst
Pharmaceuticals, Inc. (the ?Company?), with full power of substitution,
as the undersigned?s true and lawful attorney-in-fact to:
(1) prepare, execute in the undersigned's name and on the undersigned?s
behalf, and submit to the U.S. Securities and Exchange Commission (the
?SEC?) a Form ID, including amendments thereto (the ?Form ID?), and any
other documents necessary or appropriate to obtain codes and passwords
enabling the undersigned to make electronic filings with the SEC of
reports required by the Securities Exchange Act of 1934, as amended (the
?Exchange Act?), or any rule or regulation of the SEC;
(2) prepare, execute in the undersigned?s name and on the undersigned?s
behalf, and submit to the SEC, any and all Forms 3, 4, and 5 (the
?Section 16 Filings?), including amendments thereto, required to be filed
under Section 16(a) of the Exchange Act and the rules thereunder with
respect to equity securities of the Company;
(3) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute
such Form ID and any Section 16 Filings and to file such Form ID and any
Section 16 Filings with the SEC and any stock exchange or similar
authority; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of
Attorney shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in such attorney-in-
fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise of
any of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present, with
full power of substitution or revocation, hereby ratifying and confirming
that such attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this
power of attorney and the rights and powers herein granted. The
undersigned hereby authorizes, approves, and ratifies any and all prior
actions taken by such attorney-in-fact in connection with the matters
contemplated herein. The undersigned acknowledges that such attorney-in-
fact, in serving in such capacity at the request of the undersigned, does
not assume any of the undersigned's responsibilities to comply with the
Exchange Act or any rule or regulation of the SEC.
This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file a Form ID, any Section 16
Filings, or any amendments or changes thereto, with respect to the
undersigned?s holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of the date first written above.
By: /s/ Michael L. Jones
Name: Michael L. Jones
